Micro Aftermath Archived

Haemonetics Corporation (HAE) чекає на підтвердження ринку

Активність знижується — наратив втрачає актуальність.

Рейтинг 0,3

Швидкість ▲ 0,0

Статті 5

Джерела 2

Найбільш активні

Тікер	Сектор	Зміна
HAE	Health Care	+20,9%

Часова шкала настроїв

Секторна динаміка

Хронологія подій

Сер 09, 2026 Haemonetics Q1 Earnings Call Highlights Bullish

Сер 07, 2026 Haemonetics Corp Q1 Sales Increase Neutral

Тра 21, 2026 Does Haemonetics (HAE) Have Enduring Growth Potential? Neutral

Тра 12, 2026 Haemonetics Q4 Earnings Call Highlights Bullish

Кві 21, 2026 Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation Neutral

Пов'язані статті

Haemonetics Q4 Earnings Call Highlights Yahoo Finance · Тра 12, 2026 Mixed Riverwater Sustainable Value Strategy Awaits Haemonetics Corporation’s (HAE) Market Validation Yahoo Finance · Кві 21, 2026 Mixed

Найбільш активні

Тікер	Сектор	Зміна
HAE	Health Care	+20,9%

🤖 AI огляд

Детальніше

What happened: Haemonetics Corporation (HAE), a provider of blood management technologies, reported strong fiscal Q4 2025 results with revenue up 5% (9% organically) to $346 million and adjusted EPS of $1.29. For the full year, revenue reached $1.3 billion and adjusted EPS was $4.96. In Q1 2026, Haemonetics reported earnings of $33.01 million, or $0.72 per share, compared to $34.03 million, or $0.70 per share, last year. Riverwater Partners and Aristotle Capital Boston, LLC, both investment management companies, mentioned Haemonetics in their Q1 2026 investor letters, with Riverwater awaiting market validation for HAE.

Market impact: Haemonetics' robust performance has implications for the broader medical technology sector. The company's growth, driven by its Plasma and Blood Management Technologies, signals strength in the blood products market, which could benefit other players like Baxter International (BAX) and Terumo BCT. However, Riverwater's neutral stance suggests investors may be waiting for more market validation before fully committing to HAE's growth story.

What to watch next: Haemonetics' upcoming fiscal Q1 2026 earnings call on May 12, 2026, will provide further insight into the company's growth trajectory. Additionally, investors should keep an eye on the broader medical technology sector's performance, as any shifts in demand or regulatory changes could impact HAE's market validation narrative.

Огляд ШІ станом на Сер 07, 2026

Хронологія

Вперше поміченоСер 09, 2026

ОновленоСер 23, 2026